Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and efficacy of iloprost + eptifibatide in septic shock
2014-002440-41Phase 2Completed
- Sponsor
- Rigshospitalet
- Start
- Jul 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in septic shock comparing Iloprost + eptifibatide plus standard therapy with Placebo plus standard therapy (2 arms). Primary endpoint: Change in endothelial activation/damage biomarkers. Started Jul 2014; status: completed.
02
Drugs
iloprosteptifibatide
03
Conditions
septic shock
Beyond the preview
Go deeper on 2014-002440-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002440-41.